Calu-6

Calu-6 is a human lung adenocarcinoma cell line that originated from lung metastasis in lung adenocarcinoma in 1971. It exhibits epithelial morphology and has the ability to express human renin mRNA with significant increases in its steady-state levels in response to cAMP analogues and adenylyl cyclase activators. Notably, Calu-6 carries a defect in the Fanconi Anemia (FA)-BRCA pathway, which plays a vital role in tumor suppression. The growth of Calu-6 cells can be effectively hindered by Pyrogallol (PG) or Antimycin A (AMA), providing potential avenues for inhibiting their proliferation.

Why choose Calu-6 from AcceGen?

The Calu-6 cell from AcceGen exhibits several notable features. It boasts high viability, ensuring the robustness and longevity of experimental studies. It is characterized by sterility, being rigorously tested and confirmed negative for mycoplasma contamination, ensuring reliable and uncontaminated cell cultures. The cells are identified through Short Tandem Repeat analysis, ensuring their authenticity and consistency. The cells are incubated under optimal conditions, benefiting from the expertise of professional operators, who ensure precise and controlled growth environments for consistent and reproducible experimental outcomes.